Drug developers increasingly incorporate computational / in silico solutions to reduce costs and improve translation from the bench to the clinic. But even with these tools, challenges persist in determining efficacy, disease pathways, mechanism of action, toxicity, best route of administration and ideal formulation. Now, predictive AI and machine learning techniques are filling gaps previously out of reach to traditional approaches.

High level level paradigm for yielding outputs from data inputs

Role of machine learning in a “fused” framework

Bring your questions and have them answered live by our experts Dr. Jo Varshney and Dr. Jeff Barrett in this interactive online discussion on June 7, 11am PT/2pm ET. Sign up today!

Dr. Jo Varshney is the Founder and CEO of VeriSIM Life, and President and CEO of PulmoSIM Therapeutics which is a subsidiary of VeriSIM Life. She is a visionary in the fields of deep technology and preclinical drug discovery and development. Dr. Varshney is the inventor of VeriSIM Life’s BIOiSIM core technology—a unified framework combining chemical and biological modeling along with AI and ML techniques and data to predict how drugs will affect patients, to optimize portfolio management and increase clinical success. Additionally, she manages the drug assets being developed in PulmoSIM. Dr. Jo Varshney is a Doctor in Veterinary Medicine (DVM) and holds a Ph.D. in Comparative Oncology/Genomics from the University of Minnesota, as well as graduate degrees in Comparative Pathology from Penn State, and Computational Sciences from UC San Francisco. Over the past several years, Dr. Varshney has front-led numerous collaborative engagements with a host of pharmaceutical clients, government agencies, academic/medical institutes and industry innovators. She is a dynamic and celebrated leader and has received numerous accolades as well as delivered keynotes at several conferences. Her commentary on the use of technology to improve the translation of novel therapies to successful clinical outcomes has been featured in trade publications, national media and scientific journals. Additionally, she serves on several advisory boards as Scientific/Technical advisor, including the Critical Path Institute (C-Path), to further novel platforms to foster a technology ecosystem for enabling broader access to disease progression models and clinical trial simulation applications.

Dr. Jeff Barrett is the Chief Science Officer at Aridhia promoting life science partners to collaborate, access and share secure data to deliver better patient outcomes. Before Aridhia, he was Senior Vice-President at the Critical Path Institute serving as the Executive Director of the Rare Disease Cures Accelerator, Data Analytics Platform and a critical liaison between C-Path and the pharmaceutical industry, foundations, and other key stakeholders, helping grow C-Path’s portfolio in drug development solutions, with a focus, but not limited to model-informed drug development (MIDD) and real-world data (RWD) technologies. Jeff was previously Head of Quantitative Sciences at the Bill & Melinda Gates Medical Research Institute. In this role he was responsible for implementing model-based drug development, employing PK/PD modeling, statistics, and clinical trial simulations to advance the discovery and development of new medicines and vaccines.  Prior to MRI, he was Vice President, of Translational Informatics at Sanofi Pharmaceuticals.  Jeff spent 10+ years at the University of Pennsylvania where he was Professor, Pediatrics and Director, Laboratory for Applied PK/PD at the Children’s Hospital of Philadelphia. Jeff received his B.S. in Chemical Engineering from Drexel University and Ph.D. in Pharmacokinetics from University of Michigan. He has co-authored over 200 manuscripts, is fellow of ACCP, AAPS, ISOP and the recipient of numerous honors including ACCP awards for Young Investigator (2002) and Mentorship in Clinical Pharmacology (2007) and the AAPS Award in Clinical Pharmacology and Translational Research (2011). Dr. Barrett was awarded for Exceptional Innovation and Advancing the Discipline of Pharmacometrics at the International Society for Pharmacometrics (2013). He is co-Specialty Chief Editor of Frontiers in Obstetric and Pediatric Pharmacology Journal and an active member of the Child Health and Human Development Pediatrics Subcommittee as a study section reviewer.  He was a past acting chair of the FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; a voting member of the committee for 8 years.

VeriSIM Life Ask Me Anything: Mitigating translational risks with AI enabled MIDD